Cargando…

First-line cetuximab improves the efficacy of subsequent bevacizumab for RAS wild-type left-sided metastatic colorectal cancer: an observational retrospective study

The optimal targeted therapy sequence in patients of RAS wild-type left-sided metastatic colorectal cancer (mCRC) remains controversial, and few studies focus on the impact of first-line targeted agents on second-line ones. We enrolled 101 left-sided mCRC patients with RAS wild-type status, of which...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Shousheng, Jiang, Chang, Yang, Lin, Huang, Jinsheng, Peng, Roujun, Wang, Xiaopai, He, Wenzhuo, Bai, Long, Zhou, Yixin, Zhang, Bei, Xia, Liangping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378223/ https://www.ncbi.nlm.nih.gov/pubmed/32704062 http://dx.doi.org/10.1038/s41598-020-69230-5

Ejemplares similares

Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer
por: Han, Jiaqi, et al.
Publicado: (2020)

The Prognostic and Predictive Value of Carbohydrate Antigen 19-9 in Metastatic Colorectal Cancer Patients with First Line Bevacizumab Containing Chemotherapy
por: Jiang, Chang, et al.
Publicado: (2017)

Tumor microenvironment classification based on T-cell infiltration and PD-L1 in patients with mismatch repair-proficient and -deficient colorectal cancer
por: Liu, Shousheng, et al.
Publicado: (2019)

Effect of HK2, PKM2 and LDHA on Cetuximab efficacy in metastatic colorectal cancer
por: Wang, Haohua, et al.
Publicado: (2018)

First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis
por: Zheng, Bobo, et al.
Publicado: (2019)

Safety and Efficacy of Long-Term Zoledronic Acid in Advanced Breast Cancer with Bone Metastasis in South China
por: Wang, Qianyu, et al.
Publicado: (2020)

Tolerability on Serious Adverse Events of First-Line Bevacizumab and Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
por: Han, Yu Na, et al.
Publicado: (2022)

Prognostic value of total number of lymph nodes retrieved differs between left-sided colon cancer and right-sided colon cancer in stage III patients with colon cancer
por: Yang, Lin, et al.
Publicado: (2018)

Bevacizumab-containing regimens after cetuximab failure in Kras wild-type metastatic colorectal carcinoma
por: LAM, KA ON, et al.
Publicado: (2013)

Cost-Effectiveness of Anti-Epidermal Growth Factor Receptor Therapy Versus Bevacizumab in KRAS Wild-Type (WT), Pan-RAS WT, and Pan-RAS WT Left-Sided Metastatic Colorectal Cancer
por: Lee, Shing Fung, et al.
Publicado: (2021)

The Efficacy of Bevacizumab in Different Line Chemotherapy for Chinese Patients with Metastatic Colorectal Cancer
por: Yin, Chenxi, et al.
Publicado: (2016)

Metastatic lymph node ratio as a prognostic indicator in patients with stage IV colon cancer undergoing resection
por: Jiang, Chang, et al.
Publicado: (2019)

Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial
por: Boige, Valérie, et al.
Publicado: (2023)

Longterm effects of palliative local treatment of incurable metastatic lesions in colorectal cancer patients
por: Yang, Qiong, et al.
Publicado: (2016)

Bevacizumab plus chemotherapy as third- or later-line therapy in patients with heavily treated metastatic colorectal cancer
por: Yang, Qiong, et al.
Publicado: (2015)

Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer
por: Kim, Dalyong, et al.
Publicado: (2017)

HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with RAS Wild Type Metastatic Colorectal Cancer
por: Khelwatty, Said A., et al.
Publicado: (2021)

A study of gene variation in All-RAS wild-type metastatic colorectal cancer and its correlation with cetuximab
por: Tao, Huimin, et al.
Publicado: (2022)

Positive impact of the negative lymph node count on the survival rate of stage III colon cancer with pN1 and right-side disease
por: Quan, Qi, et al.
Publicado: (2019)

Pre-treatment inflammatory indexes as predictors of survival and cetuximab efficacy in metastatic colorectal cancer patients with wild-type RAS
por: Yang, Jing, et al.
Publicado: (2017)

Right- and left-sided colorectal cancers respond differently to cetuximab
por: Wang, Feng, et al.
Publicado: (2015)

Comparisons of metastatic patterns of colorectal cancer among patients by age group: a population-based study
por: Yang, Lin, et al.
Publicado: (2018)

Phase II APEC trial: The impact of primary tumor side on outcomes of first‐line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild‐type metastatic colorectal cancer
por: Price, Timothy, et al.
Publicado: (2019)

Evaluating the Optimal Sequence of Treatment With EGFR Inhibitors and Bevacizumab in RAS Wild-Type Metastatic Colorectal Cancer
por: Martins, Diana, et al.
Publicado: (2022)

Sequential cetuximab/bevacizumab therapy is associated with improved outcomes in patients with wild‐type KRAS exon 2 metastatic colorectal cancer
por: Hsu, Hung‐Chih, et al.
Publicado: (2019)

Prognostic significance of mucinous histology in left‑sided metastatic colorectal cancers with wild‑type RAS and evaluation of backbone chemotherapy regimens
por: Arikan, Rukiye, et al.
Publicado: (2023)

Comparison of UGT1A1 Polymorphism as Guidance of Irinotecan Dose Escalation in RAS Wild-Type Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab Plus FOLFIRI as the First-Line Therapy
por: Tsai, Hsiang-Lin, et al.
Publicado: (2022)

Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3
por: Fischer, Laura E., et al.
Publicado: (2022)

Considering FOLFOXIRI plus bevacizumab for metastatic colorectal cancer with left-sided tumors
por: Sunakawa, Yu, et al.
Publicado: (2018)

[(89)Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer
por: van Helden, E. J., et al.
Publicado: (2019)

FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc
por: Yu, Yiyi, et al.
Publicado: (2016)

Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab
por: Toledo, Rodrigo A., et al.
Publicado: (2016)

Mucinous Histology Is Associated with Resistance to Anti-EGFR Therapy in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer
por: Wang, Chongkai, et al.
Publicado: (2022)

Initial LDH level can predict the survival benefit from bevacizumab in the first-line setting in Chinese patients with metastatic colorectal cancer
por: Yin, Chenxi, et al.
Publicado: (2014)

Cetuximab versus bevacizumab maintenance following prior 8-cycle modified FOLFOXIRI plus cetuximab in Asian postmenopausal women with treatment-naive KRAS and BRAF wild-type metastatic colorectal cancer
por: Chen, Baomin, et al.
Publicado: (2020)

Molecular targeted treatment of metastatic colorectal cancer: the cardiovascular adverse effects of Bevacizumab and Cetuximab
por: GHERMAN, ALEXANDRA, et al.
Publicado: (2017)

Characterisation of tumor microenvironment and prevalence of CD274/PD-L1 genetic alterations difference in colorectal Cancer
por: Yang, Lin, et al.
Publicado: (2023)

Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients
por: Alonso, Vicente, et al.
Publicado: (2018)

Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy
por: Ciardiello, Davide, et al.
Publicado: (2021)

The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment
por: Ziranu, Pina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2q20gbcrmh9klb5b58978bv3jr